Completion pneumonectomy: Experience in eighty patients  by Regnard, J.F. et al.
Patients and methods
Eighty consecutive patients underwent a completion pneu-
monectomy in our department between 1972 and 1997. Of
these patients 72 (90%) were operated on in the last 15 years.
The ratio of completion pneumonectomies to standard pneu-
monectomies was around 5% during the same period. There
were 74 men and 6 women, with an average age of 58 years
(range 18-84 years). Twelve patients (15%) had previous pul-
monary insufficiency, cardiovascular disorders, or both; 12
patients (15%) had already been treated for another extratho-
racic cancer.
First operation. The initial surgical procedure was a lobec-
tomy in 71 cases, a bilobectomy in 6 cases, and a segmentec-
tomy in 3 cases. These first operations were performed for
various infectious diseases in 18 cases (bronchiectasis in 8
cases, tuberculosis in 8 cases, and lung abscess in 2 cases), for
a benign tumor in 1 case, and for primary lung cancers in 61
cases. Three of the patients with chronic infectious disease
underwent a thoracoplasty at the end of the operation. Among
the 61 cases of primary lung cancers there were 37 squamous
cell carcinomas, 16 adenocarcinomas, 4 poorly differentiated
large cell carcinomas, 2 mixed squamous cell carcinomas and
adenocarcinomas, and 2 bronchioloalveolar carcinomas.
C ompletion pneumonectomy is an operation reputedto pose difficulties in both the intraoperative and
postoperative periods, with greater risks of death and of
complications than are associated with standard pneu-
monectomy.1-7 Extensive experience is rare, and series
exceeding 50 patients are exceptional.2,3 We reviewed
our results of 80 consecutive completion pneumonec-
tomies with the objective of determining factors that
influence immediate results and long-term survival.
Objective: Because completion pneumonectomy is a procedure reputed to
place patients at risk, we reviewed our results with the objective of iden-
tifying factors that influence complications and survival. Methods: In a
25-year period, 80 completion pneumonectomies were performed after
first operations for 17 cases of benign disease and 63 cases of lung can-
cer (89% stages I and II), with 7 of the latter patients receiving postop-
erative radiotherapy. Completion pneumonectomy was performed in 18
cases of benign disease and 62 cases of lung cancer: 28 second primary
cancers, 26 recurrent cancers, 3 metastases, and 5 primary cancers in
patients previously operated on for benign disease. Results: No intraop-
erative deaths occurred. Postoperative mortality rates were 5% for the
entire series, 6.4% for patients operated on for cancer, and 0% for
patients operated on for benign diseases. Patients previously irradiated
and those operated on for infectious disease were at risk for postopera-
tive empyema and fistula formation. In the cancer treatment group the
actuarial 5-year survival was 36%, without significant difference
between patients with recurrent and second primary lung cancers. The
actuarial 5-year survivals were 51% for patients with stage I disease,
42% for patients with stage II disease, and 18% for patients with stage
IIIA disease (P < .05). Conclusions: Completion pneumonectomy can be
performed with an acceptable operative mortality rate and offers a sec-
ond chance for cure to patients with cancer. Patients previously irradi-
ated and those requiring completion pneumonectomy for infectious
benign disease are at risk for postoperative complications. (J Thorac
Cardiovasc Surg 1999;117:1095-101)
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COMPLETION PNEUMONECTOMY: EXPERIENCE IN EIGHTY PATIENTS
According to the TNM classification for lung cancers8 most
patients had localized cancers: 35 patients (58%) had stage I
disease, 19 (31%) had stage II disease, 5 (8%) had stage IIIA
disease, and 2 (3%) had stage IIIB disease. Seven of these 61
patients (11%) underwent an incomplete initial resection,
with a neoplastic bronchial margin found on definitive histo-
logic examination. Five of these 7 patients were operated on
at another hospital and underwent completion pneumonecto-
my in our department after intervals of 7, 11, 21, 21, and 22
months. Among the 2 patients initially operated on in our
department, 1 underwent an immediate reoperation whereas
the other initially received adjuvant postoperative radiothera-
py. The latter patient required a completion pneumonectomy
8 months later for recurrence. During the postoperative peri-
od after the first operation, 7 patients (all with stage III dis-
ease) received adjuvant radiotherapy (in 2 cases associated
with chemotherapy) and 4 patients received chemotherapy.
The mean dose of the delivered radiotherapy was 58 Gy
(range 45-65 Gy).
Second operation. Completion pneumonectomy was per-
formed in 18 cases for a benign lesion and in 62 cases for a
malignant tumor. The indications for completion pneumonec-
tomy among the 18 patients with benign disease were chron-
ic infected bronchiectasis destroying the remaining lobe in 12
cases and complications directly linked to the first surgical
procedure in 6 cases. There were 3 cases of bronchial anasto-
motic strictures (1 after sleeve lobectomy and 2 after standard
lobectomy) and 3 cases of bronchovascular fistulas, which
required urgent reoperation. These 3 cases of bronchovascu-
lar fistulas occurred in patients who had undergone standard
lobectomies. In the group of 61 patients with cancerous dis-
ease a second primary lung cancer or a local recurrence was
defined according to the criteria defined by Martini and
Melamed9: a local recurrence was defined as a second malig-
nant tumor with the same cell type occurring in the same
anatomic site within 2 years of the first operation and a sec-
ond primary lung cancer was defined as a second malignant
tumor when the cell type was different or when a tumor with
same cell type occurred in a different anatomic site more than
2 years after the first cancer in the absence of residual tumor
after the first operation. According to these criteria, comple-
tion pneumonectomies were performed for a second primary
cancer in 28 cases (44%), for a local recurrence of the first
cancer in 26 cases (41%), for a probable metastasis of the first
primary lung cancer in 3 cases, and for a primary lung cancer
in the 5 remaining cases of patients who had previously been
operated on for benign disease. Completion pneumonectomy
was performed on average 17 months (1-46 months) after the
initial surgical procedure in cases of local recurrence, 34
months (7-58 months) after the initial surgical procedure in
cases of metastasis, 67 months (12-131 months) after the ini-
tial surgical procedure in cases of second primary cancer, and
124 months (3-408 months) in cases of benign recurrent
lesions.
Preoperative evaluation included assessment of cardiac,
renal, and respiratory function. The selection criteria for com-
pletion pneumonectomy were the same as those for standard
pneumonectomy, mainly a predicted postpneumonectomy
forced expiratory volume in 1 second greater 33% of the theo-
retic values. The mean preoperative forced expiratory volume
in 1 second was 66% ± 14% (33%-88%) and the mean perfu-
sion of the operated side found on a lung scintiscan was 29%
(5%-33%). In the group with malignant disease assessment of
mediastinal lymph nodes was done by computed tomographic
scan, and mediastinoscopy with biopsy was performed in
response to any suspicion of N2 disease (mean diameter >1.5
cm) to avoid surgery in cases of bulky N2 disease.
Surgical procedure. Forty-six completion pneumonec-
tomies were performed on the right side and 34 were per-
formed on the left side. Extrapleural dissection was generally
performed in any area with dense adhesions and obliteration
of the pleural space. The hilar dissection was systematically
undertaken by first opening the pericardium to control the pul-
monary artery and veins. The bronchial stump was kept short,
and excessive peribronchial dissection was avoided to pre-
serve vascularization. Bronchial closure was done with sta-
plers in 60 cases and with interrupted sutures (absorbable 3-0
polyglactin Vicryl sutures; Ethicon, Inc, Somerville, NJ) in 20
cases. The line of bronchial closure was always covered with
adjacent fascial, pleural, or mediastinal tissues when avail-
able. In 5 of the patients who had received postoperative
radiotherapy after the initial surgical procedure and in 1
patient who underwent a completion pneumonectomy for
infected lesions, a serratus anterior muscle flap was performed
to reinforce the bronchial stump closure. The space was
drained by a clamped chest tube, which was left in place for
equilibration and removed 48 hours after the operation.
In the 62 patients who underwent completion pneumonec-
tomy for cancerous disease, histologic examination showed a
squamous cell carcinoma in 38 cases (61%), an adenocarci-
noma in 19 cases (31%), a mixed adenocarcinoma and squa-
mous cell carcinoma in 1 case, and an undifferentiated large
cell carcinoma in 3 cases. The stages of these resected tumors
were as follows: stage I in 28 cases (45%), stage II in 8 cases
(13%), stage IIIA in 24 cases (39%), and stage IIIB in 2 cases
(3%). In the postoperative period 17 patients received radio-
therapy, 1 patient received chemotherapy, and 1 patient
received both treatments.
Statistical analysis. Information was gathered from the
files of patients followed up in our institution or was obtained
from the referring pulmonary physicians. Follow-up of at
least 2 years, with a mean duration of 48 months, was com-
pleted at the end of 1997 for all patients. Clinical data (dura-
tion of the operation, side of the pneumonectomy, level of
blood loss, and use of transfusions) were analyzed as factors
influencing postoperative complications (simple recovery vs
empyema or bronchopleural fistula). The patients were divid-
ed into 3 subgroups: those with cancers who received adju-
vant radiotherapy after the first operation, those with cancers
who did not receive radiotherapy, and those with benign dis-
ease. The Student t test and the c 2 test were used for group
comparisons with univariate analysis. Survival was calculat-
ed from the time of completion pneumonectomy according to
an actuarial method derived from the Kaplan-Meier analy-
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sis.10 Stage of cancer was analyzed as a predictor of survival.
Survivals were compared between subgroups with the log
rank test. When appropriate, confidence intervals (CIs) are
given.
Results
No intraoperative deaths occurred. Although a hilar
dissection was systematically undertaken by first open-
ing the pericardium to control the pulmonary artery and
veins, this precaution did not avoid 3 operative vascular
injuries, all of which were immediately controlled. The
median duration of the surgical procedure was 3 hours
and 30 minutes (2-6 hours, 25%-75% CI 3-4 hours).
The median perioperative blood loss was 950 mL (250-
2500 mL, 25%-75% CI 300-2000 mL), necessitating
blood transfusions during the hospitalization in 52 cases
(66%) with a median of 3 units of packed cells per
patient (2-14 units, 25%-75% CI 1-5 units).
The overall postoperative mortality rate was 5%,
with all 4 deaths occurring among the patients with
cancerous disease. There were 1 lethal pulmonary
embolus, 1 lethal infection of the remaining lung, and
2 lethal bronchopleural fistulas with empyemas. These
2 fistulas occurred in the group of patients who had
received radiotherapy after the initial operation. In 1 of
these 2 cases a serratus anterior flap had been per-
formed but failed to prevent the occurrence of a bron-
chopleural fistula. The overall postoperative mortality
rates were 6.4% (4/62) for patients with cancerous dis-
ease and 0% for patients with benign disease. In the
group of patients who underwent completion pneu-
monectomy for lung cancer, the mortality rates were
28% (2/7) among those who had received radiotherapy
after the initial operation and 3.2% (2/55) among those
who had not (P = .18).
Postoperative recovery was uneventful in 60 cases
(75%). Twenty patients (25%) sustained nonlethal
postoperative complications, as shown in Table I. The
significant factors related to postoperative morbidity
were preliminary radiotherapy and indication of com-
pletion pneumonectomy for benign disease. In fact,
among patients operated on for cancerous disease pre-
liminary radiotherapy was significantly related to high-
er rates of postoperative empyema (42.8% vs 7.2%, P
= .05) and of bronchopleural fistula (28.6% vs 0%, P =
.02). Three bronchopleural fistulas occurred in this
select group, and 2 resulted in death (Table I). On the
other hand, the side of the pneumonectomy, the dura-
tion of the operation, the level of blood loss, the need
for red blood cell transfusions, and the stage of cancer
were not significant predictive factors for postoperative
complications.
Empyema was frequent among patients undergoing
completion pneumonectomy for benign disease
(27.7%) but did not result in any deaths. There was no
difference in bronchopleural fistula occurrence
between patients who had a hand-sewn bronchial clo-
sure and those who had a staple closure.
Actuarial survival curves are presented in Figs 1 and
2. The actuarial 5-year survival was 70% for patients
who underwent completion pneumonectomy for
benign disease. The actuarial 5-year survival was 36%
for patients who underwent completion pneumonecto-
my for cancerous disease, without any difference in
survival between patients with recurrent cancers and
those with second primary cancers (P = .75; Fig 2). As
indicated in Fig 3, the prognosis was significantly
influenced by the stage of the cancer. The actuarial 5-
year survivals were 51% (95% CI 31%-71%) for
patients with stage I disease, 42% (95% CI 25%-75%)
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Table I. Details of postoperative deaths and complications among 80 patients undergoing completion pneumonectomy
Cancers 
Overall Overall previously Other Benign 
patients cancers irradiated cancers disease 
(n = 80) (n = 62) (n = 7) (n = 55) (n = 18)
No. % No. % No. % No. % No. %
Operative death 4 5 4 6.4 2 28.6 2 3.6 0 0
Empyema 12 15 7 11.3 3 42.8 4 7.2 5 27.7
Fistula 3 3.8 2 3.2 2* 28.6 0 0 1 5.5
Hemothorax 2 2.5 1 1.6 0 0 1 1.8 0 0
Rhythmic disorder 1 1.2 1 1.6 1 14 0 0 0 0
Pulmonary embolus 1* 1.2 1* 1.6 0 0 1* 1.8 0 0
Pneumonia 1* 1.2 1* 1.6 0 0 1* 1.8 0 0
Others 2 2.5 2 3.2 0 0 2 3.6 0 0
*Lethal complications.
for patients with stage II disease, and 18% (95% CI
2%-38%) for patients with stage IIIA disease. There
was no significant difference in survival between
patients with stage I and stage II disease (P = .8),
whereas there was a significant difference between
patients with stage I and stage IIIA disease (P = .03)
and between patients with stage II and stage IIIA dis-
ease (P = .05). Both patients with stage IIIB disease
died within 3 years after the operation.
Discussion
Our results show that completion pneumonectomy
may be performed with an acceptable postoperative
mortality rate, offering some chance of long-term sur-
vival for patients with lung cancers and giving them a
second chance for cure. Our indications for completion
pneumonectomy were mainly occurrence of lung can-
cer, either recurrence of the primary lung cancer previ-
ously resected or a second primary lung cancer. In
almost a quarter of our cases, however, completion
pneumonectomy was indicated for benign lesions, most
often for infected and destroyed lobes but sometimes
also for complications related to the first resection,
either bronchovascular fistula or bronchial stenosis.
Perioperative risk and precautions. There were no
intraoperative deaths in our series, despite the reported
risk,2 especially among patients with previous radiother-
apy. However, dense adhesions and extrapleural dissec-
tion resulted in greater blood loss (median 950 mL), with
a need for transfusion in 66% of the patients.
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Fig 1. Actuarial survival of patients undergoing completion pneumonectomy either for primary lung cancer or for
benign disease. Numbers in parentheses indicate patients at risk.
Fig 2. Actuarial survival of patients with stage I, stage II, and stage IIIA lung cancers undergoing completion
pneumonectomy. Numbers in parentheses indicate patients at risk.
Radiotherapy significantly increases the density of fibro-
sis, especially in the apex of the lung. Technical factors
aiding in dissection include initial intrapericardial control
of the vessels (which may be sometimes very difficult
because of a near to total obliteration of the intrapericar-
dial space), and the “bronchus first” technique that may
facilitate the control of vessels on the right side.
Postoperative mortality rate. The overall mortality
rate was 5%, 6.4% among patients undergoing resec-
tion for malignancy and 0% among patients undergo-
ing resection for benign disease. These results compare
favorably with those in reported series (Table II). As
indicated in Tables II and III, some series have shown
higher mortality rates for benign disease2,4,7 and for
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Fig 3. Comparison of survival between patients undergoing completion pneumonectomy for second cancer with
those undergoing completion pneumonectomy for recurrent cancer. Numbers in parentheses indicate patients at risk.
Table II. Operative mortality rates and 5-year survivals after completion pneumonectomy for malignant disease
according to the literature
Patients with Overall operative Operative 
Total malignant mortality mortality rate Five-year 
Reference Year Period patients disease rate (%) for cancer (%) survival (%)
Mathisen and colleagues1 1984 — 17 17 11.8 11.8 —
McGovern and colleagues2 1988 1958-1985 113 84 12.4 11.9 26.4
Gregoire and colleagues3 1993 1969-1991 60 41 10 12.2 33
Terzi and colleagues4 1995 1982-1994 47 28 14.9 3.6 28.5
Massard and colleagues5 1995 1978-1992 37 32 10.8 12.5 44.5
al-Kattan and Goldstraw6 1995 1980-1993 38 26 2.6 0 23
Verhagen and Lacquet7 1996 1970-1993 37 33 16.2 15.3 18.3
Current series 1998 1972-1997 80 62 5 6.5 35
Table III. Operative mortality and major complication rates after completion pneumonectomy for benign disease
according to the literature
Operative Bronchopleural 
Total Patients with mortality Empyema fistula 
Reference Year Period patients benign disease rate (%) rate (%) rate (%)
McGovern and colleagues2 1988 1958-1985 113 29 13.8 10.6 6.2
Gregoire and colleagues3 1993 1969-1991 60 19 5.3 — 13.3
Terzi and colleagues4 1995 1982-1994 47 17 35 — —
Massard and colleagues5 1995 1978-1992 37 5 0 8.1 2.7
al-Kattan and Goldstraw6 1995 1980-1993 38 12 8.3 — —
Verhagen and Lacquet7 1996 1970-1993 37 4 25 — —
Current series 1998 1972-1997 80 18 0 15 3.8
completion pneumonectomy after initial bronchial
sleeve resection.11 In contrast to McGovern and col-
leagues,2 we did not observe any difference in postop-
erative mortality rate between patients with second pri-
mary cancers and recurrent cancers, and our 5% overall
mortality rate is close to that seen for standard pneu-
monectomy in our institution and in the literature.12,13
Postoperative complications. Preoperative radio-
therapy increases the bronchopleural fistula rate after
lung resections.14,15 We especially saw major postoper-
ative complications among patients who received adju-
vant radiotherapy after the initial resection. To prevent
bronchopleural fistula formation, reinforcement of the
stump (with muscle, pericardial fat, pleura, or omen-
tum) is recommended. As we reported previously,16 we
favor a muscle flap. As with Arnold and Pairolero,17 the
serratus anterior muscle is the first choice, but other
flaps such as the latissimus dorsi flap5,18 or the omental
flap19 may also be used. In this study the use of a ser-
ratus anterior muscle flap failed to avoid the occurrence
of 1 fistula among the patients previously irradiated.
Despite this precaution, these patients thus remain at
risk for major complications. Not surprisingly, in our
series empyema was more frequent after completion
pneumonectomy for infectious disease than for lung
cancer (28.6% and 11.3%, respectively). McGovern
and colleagues2 reported similar rates (20.6% and
10.6%, respectively). In contrast to McGovern and col-
leagues,2 however, who reported a higher rate of bron-
chopleural fistulas among patients who underwent
completion pneumonectomy for benign disease than
among those operated on for cancer (17.2% vs 5.5%),
we did not observe any statistical difference between
these groups (5.5% and 3.1%, respectively). The poten-
tial risk factors for development of empyema and bron-
chopleural fistula after completion pneumonectomy for
infectious disease are presumably the same as after
standard pneumonectomy: poor general condition, spu-
tum revealing mycobacteria, perioperative polymicro-
bial contamination of the lung, and Aspergillus species
infection.2,5,20-23 In these situations immediate muscle
transposition could also be a good option to prevent the
occurrence of a bronchopleural fistula.
Long-term survival among patients with cancer.
In our study we found an overall 5-year survival among
patients with cancer of 36%, despite the fact that 45%
of the patients had stage III disease. Completion pneu-
monectomy undoubtedly offers a second chance for
cure to patients with cancer. The prognosis was closely
dependent on the stage of cancer (Fig 2).
In this series we did not find any difference in sur-
vival between patients with second cancers and with
recurrent cancers, in contrast to 2 other studies2,3 that
reported a better survival after completion pneumonec-
tomy among patients with second primary cancers. The
distinction between a second primary cancer and recur-
rent cancer is of only academic importance, however, if
the tumor can be radically resected. These results sup-
port the need to carefully follow up patients with lung
cancer after initial resection, because 45% of patients
in our series underwent completion pneumonectomy
for an advanced stage III cancer. Patients with a first
resected low stage (stage I or II) cancer obviously may
benefit the most from the follow-up because they are
the best candidates for a second curative procedure.
Efforts should be made to focus the follow-up on these
patients, who are at risk for development of a second
new primary cancer and sometimes a recurrence. The
prognosis after completion pneumonectomy for lung
cancer is relatively close to the commonly accepted
norms for standard primary resection for equal stages
of cancer.24
Conclusion
This series demonstrates the feasibility and benefits
of completion pneumonectomy for patients with new
primary or recurrent lung cancers, with postoperative
mortality rates and survivals that are comparable to
those associated with standard pneumonectomy.
Patients who received adjuvant radiotherapy after the
first resection are at risk for bronchopleural fistula for-
mation, which should be prevented by covering the
bronchial closure with a muscle flap. Empyema was
more frequent after completion pneumonectomy for
infectious disease but did not result in any deaths.
Intensive follow-up of patients previously operated on
for a low stage cancer is recommended to give these
patients a second chance for cure in cases of new pri-
mary or recurrent cancers.
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